Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micafungin vs standard care for prevention of invasive fungal disease in high-risk liver transplant recipients
2008-005214-49Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of micafungin in invasive mycoses and mycoses (2 arms), sponsored by Astellas Pharma. Primary endpoint: Clinical success. Started Aug 2009; status: completed.
02
Drugs
micafungin
03
Conditions
invasive mycosesmycoses
Beyond the preview
Go deeper on 2008-005214-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005214-49.